GlobeNewswire
Rixubis (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
📈
AI Sentiment
Highly Positive
9/10
Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) News
Latest updates and market news for TAK
8 news
Mar 7 - Mar 13, 2026
Page 1
Zacks
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Hemofil M (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
📈
AI Sentiment
Highly Positive
9/10
GlobeNewswire
ADZYNMA (Takeda Pharmaceutical: ADAMTS13, recombinant-krhn) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Actos Class Action Puts Eli Lilly Legal And Cash Flow Risks In Focus
📉
AI Sentiment
Negative
3/10
Insider Monkey
FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment
📈
AI Sentiment
Highly Positive
9/10
MarketWatch
These 8 drugs could help fight dementia — and they’re already on the market
📊
AI Sentiment
Positive
6/10
Simply Wall St.
Eli Lilly Weighs Employer Growth Potential Against Fresh Actos Legal Risk
📊
AI Sentiment
Positive
6/10
Share this news page